BeamMed now officially promotes AEYE Health’s groundbreaking AI diagnostic screening technology
By OurCrowd Team
BeamMed is proud to announce its official promotion of AEYE Health’s state-of-the-art AI diagnostic screening system, AEYE-DS. Developed in Israel, the AEYE solution seamlessly integrates with portable cameras (Optomed Aurora) as well as tabletop cameras to deliver fast, efficient, and highly accurate diabetic retinopathy screenings. This pioneering technology is now available through a flexible monthly subscription model, with a minimum commitment of twelve months. This subscription offers unlimited scans and on-site interpretations that are FDA approved, with an option to include the handheld cameras for clinics that do not already have them.
Revolutionizing Diabetic Retinopathy Screening with Rapid, Accurate AI-Based Exams
AEYE Diagnostic Screening (AEYE-DS) utilizes advanced artificial intelligence to instantly diagnose diabetic retinopathy from retinal images. It is the only FDA-cleared solution providing autonomous, immediate AI diagnosis using both handheld and tabletop cameras, enabling a one-minute diabetic eye exam at any point of care.
Key Benefits of AEYE Diagnostic Screening
Highly Accurate and Efficient
- 1-Minute Exam: The screening takes only about one minute on average, making it exceptionally fast for point-of-care diagnostics.
- Best-in-Class Performance: Proven to deliver high accuracy with robust sensitivity and specificity in desktop solutions.
Versatile and Practical Application
- Multiple Imaging Options: Compatible with both desktop and portable handheld cameras, the system offers increased flexibility across various clinical settings.
- Simplified Process: Only one image per eye is required, and dilation is rarely necessary, streamlining the exam process and making it accessible for a wide range of healthcare staff.
Immediate Results and Workflow Integration
- Instant Diagnostic Report: The AI system provides immediate diagnostic reports, enabling on-the-spot decision-making and streamlining patient management.
- Point-of-Care Screening: By empowering primary care physicians to perform diabetic retinopathy screenings during routine visits, the technology eliminates delays associated with specialist referrals.
Economic and Care Quality Benefits
- Reimbursable Procedure: With a dedicated CPT code (92229) and alignment with HEDIS/Star quality measures, the screening is not only cost-effective but also instrumental in closing care gaps.
- Closing the Diabetic Eye Exam Gap: With traditional referral-based screening adherence ranging from only 15% to 50%, this autonomous solution offers a practical alternative to ensure timely diagnosis and treatment.
Future Expansion
- Broader Diagnostic Potential: While the current focus is on diabetic retinopathy, the underlying AI platform is being extended to detect other conditions such as glaucoma and age-related macular degeneration, further broadening its impact on eye health.
About BeamMed
BeamMed is committed to advancing healthcare through innovative technology solutions that enhance clinical workflows and improve patient outcomes. By promoting breakthrough tools like AEYE Health’s diagnostic screening system, BeamMed continues to drive the future of accessible, high-quality, and efficient healthcare services.